Skip to search formSkip to main contentSkip to account menu

ZD 6126

Known as: Vascular Disrupting Agent ZD6126, ZD-6126, ZD6126 
A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo… 
National Institutes of Health

Related topics

Related topics

3 relations
ANG453Microtubule Processfluorouracil/leucovorin calcium/oxaliplatin/ZD6126

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Cardiovascular toxicity profiles of vascular-disrupting agents.
BACKGROUND Vascular-disrupting agents (VDAs) represent a new class of chemotherapeutic agent that targets the existing… 
Review
2010
Review
2010
Microtubule-Binding Natural Products for Cancer Therapy
Abstract Natural products, especially microtubule-binding natural products, play important roles in the war against cancer. From… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
Highly Cited
2006
Highly Cited
2006
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
PURPOSE ZD6126 is a novel vascular-targeting agent that induces selective effects on the morphology of endothelial cells by… 
Highly Cited
2005
Highly Cited
2005
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
PURPOSE The effect of ZD6126 on tumor oxygen tension and tumor growth delay in combination with ionizing radiation was examined… 
Review
2004
Review
2004
Vascular Targeting Agents as Cancer Therapeutics
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… 
Highly Cited
2004
Highly Cited
2004
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of…
OBJECTIVE Targeting the tumor vasculature may offer an alternative or complementary therapeutic approach to targeting growth… 
Highly Cited
2003
Highly Cited
2003
Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
The tubulin-binding agent ZD6126 is a novel vascular-targeting agent in clinical development for the treatment of solid tumors… 
Highly Cited
2002
Highly Cited
2002
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow.
The effect of antivascular therapy on blood flow in superficial tumors was monitored using novel high frequency Doppler (HFD… 
Highly Cited
2002
Highly Cited
2002
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)